NCT00757549View on ClinicalTrials.gov

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

October 25, 2017

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

cetuximab

DRUG

cisplatin

GENETIC

TdT-mediated dUTP nick end labeling assay

OTHER

3'-deoxy-3'-[18F]fluorothymidine

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

RADIATION

fludeoxyglucose F 18

RADIATION

radiation therapy

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00757549 - 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx | Biotech Hunter | Biotech Hunter